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ABSTRACT
Objective: A simple, selective, sensitive, specific, and spectrophotometric method has been developed for the detection of imatinib mesylate in pure 
form and formulations.
Methods: The analytical condition was optimized for the drug, carried out as per the International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use guidelines.
Results: The drug shows absorption at 232.0 nm and obeyed beers law in the wide concentration range from 0.5 to 4.0 µg/ml. The lower limit of 
detection was found to be 0.331 µg/ml and the limit of quantification to be 1.004 µg/ml. The regression equation was found to be y = 0.08x. The 
precision of the method was found to be 99.04%±0.527% and the percentage of drug recovered by this method is 100.13%±1.375%.
Conclusion: The method is simple and suitable for determination for imatinib mesylate in pure and pharmaceutical preparation.
Keywords: Spectrophotometer, Imatinib mesylate, Determination.
INTRODUCTION
Imatinib mesylate is a prescribed cancer drug for the treatment of 
leukemia and gastrointestinal tumors. It works by inhibiting cancer cell 
growth-related proteins to relieve symptoms, prevent cancer cells from 
spreading, and help other treatments. Imatinib mesylate is one of the 
newest anticancer drugs on the market and was one of the first drugs 
to be pushed through the Food and Drug Administration quick track 
approval designation. The drug is designed to be inhibitors of Bcr-Abl 
tyrosine kinase inhibitors and is used to treat chronic myeloid leukemia 
and gastrointestinal stromal tumors.
Imatinib mesylate’s chemical name is 4-4[(4-methyl-1-piperazinyl) 
methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]phenyl]-
benzamide mono methanesulfonate. It has C29H31N7O.CH4O3S molecular 
formula and a 589.71 molecular weight. It has the structural formula 
which is presented in Fig. 1. Imatinib mesylate is a white crystalline 
powder distilled water, 0.1 N HCl, methanol, and dimethyl ether 
sparingly soluble [1]. Review of literature reveals that only a few 
methods such as ultraviolet (UV) [2-7], colorimetery [8,9], biological 
fluid using high-performance liquid chromatography (HPLC) [10], 
reversed phase-HPLC [3,11-13], LC [14-16], LC-mass spectrometry [17] 
and ultrafast LC [18] were developed for the determination of imatinib 
mesylate in pure and pharmaceutical preparation.
MATERIALS
Instruments
Absorption spectral measurements were carried out with a Systronics 
2202 UV-visible spectrophotometry and for sonication Branson 2510 
Sonicator was used.
Chemicals
Imatinib mesylate obtained as a gift sample from Aspen Biopharma, 
Hyderabad, Telangana. Imatinib mesylate tablet formulations (100 mg) 
were procured from local pharmacies. Hydrochloric acid was of AR 
grade from Nice Pharmaceuticals Pvt. Ltd., and in house produced 
distilled water was used.
METHODS
Preparation of stock solution
About 100 mg of mg imatinib mesylate drug in pure form was weighed 
quantitatively and transferred to a 100 ml standard measuring flask, 
0.1 M HCl was added to the above flask, dissolved, and sonicated for 
15 min, and the capacity was made up to100 ml with 0.1 M HCl to obtain 
a final concentration of 1 mg/ml.
Determination of absorbance maxima
An appropriate aliquot portion of 2 ml of imatinib mesylate from a stock 
solution of imatinib mesylate was moved to 100 ml standard measuring 
flask, mixed with 0.1 N HCl and the volume was made up to 100 ml with 
0.1 N HCl to obtain the concentration 20 µg/ml of imatinib mesylate. 
Drug solutions were scanned in spectrophotometry and the absorbance 
maxima were determined.
Validation of the proposed method
The anticipated method was authenticated as per the International 
Council for Harmonisation Q2 (R1) guidelines for linearity, range, 
accuracy, precision, stability, limit of detection (LOD), and limit of 
quantification (LOQ) [19].
Linearity and range
An appropriate aliquot portion of 0.5, 1, 1.5, 2, 2.5, 3, 3.5, and 4 ml of 
imatinib mesylate from standard solution was transferred to 100 ml 
standard measuring flasks and dissolved in 0.1 M HCl volumes were 
made up to 100 ml with same solvents to obtain 0.5, 1, 1.5, 2, 2.5, 3, 
3.5, and 4 µg/ml concentrations of imatinib mesylate. The absorbance 
of all the subsequent solutions was measured at 232.0 nm. The 
calibration curve was constructed by plotting drug concentration 
versus absorbance.
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Precision
Ten tablets were weighed accurately and crushed into a fine powder. 
An accurately weighed quantity of powder equivalent to 100 mg of 
imatinib mesylate was transferred to 100 ml volumetric flask. About 
25 ml of 0.1 M HCl was added and sonicated for 5 min, made up the 
volume with 0.1 M HCl and filtered. The resulting filtrate was measured 
at 232.0 nm using spectrophotometry.
Accuracy
A working standard solution of imatinib mesylate was prepared with 
0.1 M HCl in a concentration of 2 mg/ml. Equivalent to 50 mg of imatinib 
mesylate (about 99 mg of tablet powder) weighed accurately and moved 
into three different 100 ml standard measuring flasks. About 25 ml of 
0.1 N HCl was added and 12.5 ml (50%), 25 ml (100%), and 37.5 ml 
(150%) of the standard solution were added which contains 2 mg/ml 
of imatinib mesylate. The solution was sonicated for 5 min, made up 
the volume up to 100 ml with 0.1 N HCl. The resulting solutions were 
filtered separately and the filtrate of the solution was used to measure 
the absorbance at 232.0 nm using 0.1 N HCl as solvent blank. It was 
repeated for three times of different weighing at each level so that nine 
different weighings were performed.
LOD
The detection limit of a distinct analytical practice is the lowest amount 
of substance in a mixture which can be detected but not essentially 
quantitated as an exact value.
Limit of quantitation
The quantitation limit of a distinct analytical practice is the lowest 
analyte in a sample which can be quantitatively quantified with suitable 
precision and accuracy.
Ruggedness
Ruggedness is a degree of reproducibility of test outcomes under 
normal, predictable operational situations from laboratory to 
laboratory and from analyst to analyst. Ruggedness is determined by 
the analysis of aliquots by a different analyst. About 2 µg/ml solutions 
were prepared and analyzed using a spectrophotometer.
Robustness
The robustness of an analytical practice is a measure of capacity to remain 
unaffected by small, but deliberate variations in method parameters 
and provides an indication of its reliability during normal usage. It was 
carried out by changing the wavelength by spectrophotometry with 
1 nm difference in wavelength at 231 nmm and 233 nm, respectively.
Stability study
Stability study is an integral part of much analytical procedure. The tests 
are based on the concept that the equipment, electronics, analytical 
operation, and samples to be analyzed constitute an integral system that 
can be evaluated as such. Stability test parameter is to be established 
for a particular procedure depends on the type of procedure being 
validated. It was carried out by 2 µg/ml solution which was prepared 
and measured for 2 h with the interval of 30 min at 232.0 nm using 
spectrophotometer.
RESULTS AND DISCUSSION
Determination of absorption maximum
Imatinib mesylate is a UV absorbing fragment with definite 
chromophores in the structure that absorbs at a specific wavelength 
and this fact was effectively used for their quantitative determinations 
using the UV spectroscopic method. An absorbance maximum was 
determined in spectrophotometry by taking 2 µg/ml imatinib mesylate 
drug which is dissolved in 0.1 N HCl and scanned from 200 to 400 nm 
using UV-visible spectrophotometer. The absorption spectra presented 
in Fig.  2.  The  spectral  analysis  showed  that  the  λ  max  of  imatinib 
mesylate was found to be at 232.0 nm in 0.1 N HCl.
Validation of the proposed method
Linearity and range
Calibration standards for imatinib mesylate covering a range of 
0.5–4 µg/ml were prepared in serial dilutions that were made with 
Fig. 1: Structure of imatinib mesylate
Fig. 2: Ultraviolet-spectrum of imatinib mesylate
Table 1: Linearity of imatinib mesylate









Table 2: Precision of imatinib mesylate
S. No. Weight of 
the tablet 
powder (mg)




1. 0.1977 0.168 99.40 99.40
2. 0.1974 0.167 98.81 98.81
3. 0.1976 0.168 99.40 99.40
4. 0.1975 0.166 98.22 98.22
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Table 3: Recovery of imatinib mesylate



















1. 50 0.1002 50 25 75 0.128 77.5 27.5 102.8
2. 50 0.1006 50 25 75 0.122 74.5 22.9 99.2
3. 50 0.1007 50 25 75 0.121 73.5 23.3 99.4
4. 100 0.1001 50 50 100 0.164 98.3 48.3 98.6
5. 100 0.1005 50 50 100 0.165 100 50 100.0
6. 100 0.1007 50 50 100 0.169 102 52 102.0
7. 150 0.1004 50 74 124 0.204 123.5 73.5 99.3
8. 150 0.1003 50 74 124 0.206 124 74 100.0




Table 4: Ruggedness of imatinib mesylate





Table 5: Robustness of imatinib mesylate




Table 6: Stability study of imatinib mesylate
S. No. Time (h) Absorbance (nm)
1. 0 min 0.179
2. 30 min 0.175
3. 1 h 0.170
4. 2 h 0.091
Table 7: Validation profile of imatinib mesylate
Parameters Values








LOD: Limit of detection, LOQ: Limit of quantification
0.1 N HCl. The absorbance of all resulting concentrations was measured 
at 232 nm. The graph between the concentration and absorbance 
was plotted. The regression equation was found to be y = 0.08x. The 
correlation coefficient (R2) of the standard curve was found to be 0.993. 
The obtained data are presented in Table 1. It was found to be linear 
and hence suitable for the estimation of the drug.
Precision
The results of the precision data were presented in Table 2 for 
spectrophotometry. The values obtained in the repeatability (precision) 
shows that there is no significant difference in the precision value. 
Hence, the developed method can be used to analyze the imatinib 
mesylate in the tablet formulation. There is no evidence of interference 
of excipients with imatinib mesylate drug.
The mean precision value was found to be 99.046±0.53%. The value 
was obtained from 98.22% to 99.4% by spectrophotometric method.
Accuracy
From the data, drug – excipients interactions and/or drug – solvent 
interactions have not been observed. Since the standard deviation is 
less than 2% and the mean was above 100%, it was confirmed that 
there is no interference of any component as excipient  is observed by 
this method. The three level accuracy data is presented in Table 3.
The percentage of recovery was found to be 100.13±1.37%. The value 
was obtained from 98.6% to 102.85% by spectrophotometric method.
LOD and LOQ
The LOD was found to be 0.331 µg/ml and the LOQ concentration was 
found to be 1.004 µg/ml.
Ruggedness
Ruggedness data are presented in Table 4 by the spectrophotometric 
method, which do not show any significant difference in the absorbance. 
Hence, the developed method is rugged.
Robustness
There is no significant difference in absorbance observed when the 
minor changes like the one nanometer difference in spectrophotometric 
estimation. The observed data were presented in Table 5.
Stability study
The data show (Table 6) that until the end of 1.5 h, there is no 
significant difference observed. At the same time after the time within 
2 h, the absorbance was drastically reduced. Hence, it was inferred that 
the sample solution may be stable up to 1.5 h from the preparation of 
the sample solution.
Validation profile
Performing replicate analysis of the standard solutions was used to 
assess the accuracy and precision and reproducibility of the proposed 
methods. The selected concentration for the drug imatinib mesylate 
within the calibration range was prepared in 0.1 N HCl and analyzed 
with the relevant calibration curves to determine the intra-day and 
inter-day variability. The intra-day and inter-day precision were 
determined and presented in Table 7.
Estimation of imatinib mesylate by the developed method ensures the 
selective method than the other methods. The other methods require 
costly instrument which incurs the cost of analysis and the UV method 
which has also published do have other solvents. Stability of the solution 
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also found to be significantly acceptable range for the routine analysis. 
This method shows a wide range for linearity and most effective method 
to determine the said drug in the formulation and as pure form.
CONCLUSION
Spectrophotometric method for quantifying imatinib mesylate in pure 
and formulation has been developed and validated. The developed 
method is selective, precise, accurate, and linear over the concentration 
range from 0.5 to 4 µg/ml. The precision was found to be 99.04%±0.527%. 
The percentage of drug recovered 100.13%±1.375%. The LOD and LOQ 
were found to be 0.331 µg/ml and 1.004 µg/ml, respectively, with 0.1 M 
HCl. The developed method is simple and suitable for determination for 
imatinib mesylate in pure and pharmaceutical preparations.
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